Modulating Wnt Signaling Pathway to Enhance Allograft Integration in Orthopaedic Trauma Treatment
Abstract
The research project was designed to test a novel approach of modulating Wnt signaling pathway in the bone tissue repair by using monoclonal antibodies against sclerostin (Sost) and DKK-1 (donated by Amgen Inc., Thousand Oaks, CA under MTA). Since the previous annual report, the project has progressed at a rapid pace. After overcoming the technical issue with allograft placement, we have performed all the surgical procedures, harvested approximately 85% of the test material (remaining will be completed by mid-December 2012), analyzed approx. 10% of the samples by mu CT (data presented in this report), banked the remaining samples. The initial assessment of the data is encouraging as it reveals that the use of anti-Sost or anti-Dkk-1 antibodies enhances new bone formation around the allograft. The mechanical testing the regenerated region has not been performed but likely to support our hypothesis of improved integration.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA581575
Entities
People
- Amarjit S. Virdi
Organizations
- Rush University